Thursday, October 29, 2015

Auvi-Q and Allerject Recall

The Auvi-Q has returned in ownership to its original inventors and their company, kaléo. An updated post will be published. 

Voluntary, Precautionary Recall of ALL 
Auvi-Q and Allerject Epinephrine Auto-Injectors
Due to Potential Inaccurate Dosage Delivery

Click here to watch a video from the Dr. Paul Chew, Global Chief Medical Officer, Sanofi

Click here for details on the reimbursement process.

Recall details can be found here (U.S.) and here (Canada.) I reached out to Sanofi US to get some clarification on a few issues and received the following information: (emphasis and [comments] added...)

  • The Sanofi US voluntary recall includes ALL Auvi-Q® (epinephrine injection, USP) devices currently in the market.  The Lot number information shared in our announcement includes every consecutive lot number beginning with #2299596 through 3037230
    • (I'm still awaiting on specific clarification on the set I have, which expires 10-2015 and has a lot number that does not fall in the noted range. Though it may only be "good" for another few days, it will have to be my backup until I can get replacement EAIs.)
  • This recall is specific to Auvi-Q in the U.S. and Allerject in Canada
  • People with Auvi-Q devices should immediately contact their healthcare professional for a prescription for an alternate epinephrine auto-injector [e.g. Adrenaclick, EpiPen, Generic Epinephrine]
  • They can then call 1-866-726-6340 for information about how to return their Auvi-Q devices (Due to high volume of calls being received on the Auvi‑Q customer service phone line, callers may periodically receive a message that the line is down. We appreciate your patience and please call back.) 
    • [A second line has been added, due to the high call volume: 1-877-319-8963)
  • Sanofi US will reimburse patients for the full out-of-pocket cost [of the newly purchased EAIs] when they receive a new epinephrine auto-injector [with proof of purchase - so save your receipts!]
  • Information and updates about the recall will be posted as they are available on

No comments:

Post a Comment